Switch theme
Sign up to access all valuation multiples
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
1999
28
LTM Revenue $9.7M
LTM EBITDA n/a
-$4.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SCYNEXIS has a last 12-month revenue of $9.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SCYNEXIS achieved revenue of $3.7M and an EBITDA of -$20.3M.
SCYNEXIS expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SCYNEXIS valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $140M | $3.7M | XXX | XXX | XXX |
| Gross Profit | $4.5M | $125M | XXX | XXX | XXX |
| Gross Margin | 3% | 3324% | XXX | XXX | XXX |
| EBITDA | $70.9M | -$20.3M | XXX | XXX | XXX |
| EBITDA Margin | 51% | -542% | XXX | XXX | XXX |
| Net Profit | -$62.8M | $67.0M | XXX | XXX | XXX |
| Net Margin | -45% | 1790% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SCYNEXIS's stock price is $1.
SCYNEXIS has current market cap of $38.5M, and EV of -$4.6M.
See SCYNEXIS trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$4.6M | $38.5M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SCYNEXIS has market cap of $38.5M and EV of -$4.6M.
SCYNEXIS's trades at -0.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SCYNEXIS and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$4.6M | XXX | XXX | XXX |
| EV/Revenue | -1.2x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSCYNEXIS's NTM/LTM revenue growth is 322%
SCYNEXIS's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.5M for the same period.
Over next 12 months, SCYNEXIS's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SCYNEXIS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SCYNEXIS and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -97% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -542% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -129% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -220% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 705% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1091% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SCYNEXIS acquired XXX companies to date.
Last acquisition by SCYNEXIS was XXXXXXXX, XXXXX XXXXX XXXXXX . SCYNEXIS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SCYNEXIS founded? | SCYNEXIS was founded in 1999. |
| Where is SCYNEXIS headquartered? | SCYNEXIS is headquartered in United States of America. |
| How many employees does SCYNEXIS have? | As of today, SCYNEXIS has 28 employees. |
| Who is the CEO of SCYNEXIS? | SCYNEXIS's CEO is Dr. David Angulo, M.D.. |
| Is SCYNEXIS publicy listed? | Yes, SCYNEXIS is a public company listed on NAS. |
| What is the stock symbol of SCYNEXIS? | SCYNEXIS trades under SCYX ticker. |
| When did SCYNEXIS go public? | SCYNEXIS went public in 2014. |
| Who are competitors of SCYNEXIS? | Similar companies to SCYNEXIS include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SCYNEXIS? | SCYNEXIS's current market cap is $38.5M |
| What is the current revenue of SCYNEXIS? | SCYNEXIS's last 12-month revenue is $9.7M. |
| What is the current EV/Revenue multiple of SCYNEXIS? | Current revenue multiple of SCYNEXIS is -0.5x. |
| What is the current revenue growth of SCYNEXIS? | SCYNEXIS revenue growth between 2023 and 2024 was -97%. |
| Is SCYNEXIS profitable? | Yes, SCYNEXIS is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
